

**Summit Corporation plc**  
(“Summit” or “the Company”)

**NEW POSITIVE DATA FROM C. DIFFICILE PROGRAMME PRESENTED AT 51<sup>ST</sup> ICAAC CONFERENCE**

**Oxford, UK, 19 September 2011**, Summit (AIM: SUMM), a UK drug discovery company, announces that it is presenting new positive data from its antibiotic programme targeting infections caused by the ‘superbug’ *Clostridium difficile* at the 51st annual Interscience Conference on Antimicrobial Agents and Chemotherapy (‘ICAAC’) being held in Chicago, US, between 17 and 20 September 2011.

ICAAC is the premier meeting on infectious diseases and anti-microbial agents and brings together selected world-renowned scientists in the field to present their latest research.

**Commenting on the news, Summit’s Chief Scientific Officer, Richard Storer, DPhil, said:**

*“C. difficile infection (‘CDI’) is a serious medical issue that remains poorly treated. Summit’s programme, which has been supported by a prestigious grant from the Wellcome Trust, has identified a novel class of antibiotics that have the ideal profile to address the key clinical issues.*

*“The data being presented at ICAAC highlight our preclinical development candidate SMT 19969 and includes the reporting of new positive results from non-clinical efficacy studies in the gold standard disease model in which it showed superiority over the antibiotic vancomycin, the current standard of care. Summit is very excited about the prospects for SMT 19969 as we believe it has the profile to become the front-line antibiotic of choice to treat CDI.”*

The data are being presented by Summit and two key opinion leaders in the field who have been collaborating with the Company in the development of the programme. Details of the presentations are as follows:

***“SMT19969: A novel antibiotic for C. difficile infection; C. difficile growth inhibition, spectrum of activity and resistance development”***

Presenter: Richard Vickers, PhD, Associate Director and Principal Investigator, Summit.  
Monday, 19 September 2011 at 11:15-13:15 CDT  
Presentation number: B-1194, session 167

***“Efficacy of SMT19969 and SMT21829 in a hamster model of Clostridium difficile associated disease”***

Presenter: William Weiss, Director of Preclinical Services, University of North Texas Health Science Centre in Fort Worth, US  
Monday, 19 September 2011 at 11:15-13:15 CDT  
Presentation number: B-1195, session 167

***“Efficacy of novel antimicrobial agent SMT19969 against simulated Clostridium difficile infection in an in vitro human gut model”***

Presenter: Professor Mark Wilcox, Consultant and Clinical Director of Microbiology and Pathology, Leeds Teaching Hospitals NHS Trust, UK.  
Monday, 19 September 2011 at 11:15-13:15 CDT  
Presentation number: B-1193, session 167

## **SMT 19969: A targeted antibiotic for the treatment of *C. difficile* infection**

*C. difficile* infection represents a serious medical issue in hospitals and long-term care homes and there is growing concern about its spread to the wider community. The combined annual cost of care in Europe and North America is estimated at over \$7 billion.

The major clinical issue in treating CDI is preventing recurrent disease because repeat episodes of infection are often more severe. The severity of the disease is also increasing due to infection caused by hypervirulent *C. difficile* strains such as BI/NAP1/027. The limited treatment options currently available are failing to address these clinical challenges.

The presentations at ICAAC report the results from a series of non-clinical efficacy studies, including those undertaken in a human gut model of CDI and the gold standard *in vivo* disease model, to highlight how Summit's programme addresses the key clinical challenges.

In summary the results show that Summit's preclinical development candidate, SMT 19969, has an unprecedented profile when compared to antibiotics that are currently on the market to treat CDI. SMT 19969 combines potent activity against a comprehensive panel of *C. difficile* clinical isolates, including hypervirulent, endemic and emerging strains, with exceptionally high levels of antibacterial selectivity. This selectivity means there is a lack of disruption to the healthy gut bacteria and this is important in naturally preventing recurrence of CDI and improving the prognosis for patients.

New data generated from studies conducted in the gold standard *in vivo* disease model show that SMT 19969 is superior in treating CDI, including infection by the hypervirulent BI/NAP1/027 strain, compared to the current standard of care vancomycin.

In addition the compound is targeted exclusively to the site of infection in the GI tract, shows exceptionally low levels of resistance development and has an excellent safety profile.

Summit's programme is supported by a Seeding Drug Discovery Award from the Wellcome Trust and the programme recently achieved a further research milestone following nomination of SMT 19969 as the preclinical development candidate. SMT 19969 remains on-target to commence human clinical trials in Q3 2012.

The presentations are available on request from [investors@summitplc.com](mailto:investors@summitplc.com).

- END -

### **For more information, please contact:**

#### **Summit**

Barry Price, PhD,  
Richard Pye, PhD

Tel: +44 (0)1235 443 951

#### **Singer Capital Markets (Nominated Adviser)**

Shaun Dobson / Claes Spång

Tel: +44 (0)20 3205 7500

#### **Peckwater PR**

Tarquin Edwards

Tel: +44 (0)7879 458 364

[tarquin.edwards@peckwaterpr.co.uk](mailto:tarquin.edwards@peckwaterpr.co.uk)

## Notes to Editors

### About Summit

Summit is an Oxford, UK based drug discovery company with an innovative technology platform called Seglins for the discovery of new medicines, a portfolio of drug programme assets and a commercial strategy of signing multiple early-stage deals.

Seglin™ technology is using new chemistry to access biological drug targets that cannot be exploited by conventional drug discovery approaches. Summit's internal research is currently focussed in high-value therapy areas and the Company will further exploit the technology's wider potential through strategic alliances. Summit's programme portfolio consists of a number of drug programmes targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and *C. difficile* infection.

Summit's commercial strategy focuses on signing multiple early-stage drug programme and technology platform deals that generate upfront cash, transfer development costs from the Company, and retain valuable upside potential.

Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at [www.summitplc.com](http://www.summitplc.com).

### Forward Looking Statements

*This document contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipates", "intends", "plans", "seeks", "believes", "estimates", "expects" and similar references to future periods, or by the inclusion of forecasts or projections. Forward-looking statements are based on the Company's current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. The Company cautions you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements and regional, national, global political, economic, business, competitive, market and regulatory conditions.*